The "DDR on DTC" column in the August 2012 issue of MM&M magazine ripped into a print ad that showed a woman migraine sufferer being able to mop the floor after taking the Pfizer anti-migraine headache drug Replax.
"DTC ads used to be over-aspirational," said the author, Deborah Dick-Rath, "we saw relieved arthritis sufferers running marathons or playing Frisbee. With Relpax, the insight seems to be that sufferers just aspire to do such everyday activities as mopping the floor...We hope that Relpax is a success for Pfizer and that migraine sufferers find relief. We also hope they get (strictly aspirationally) excused from swabbing the deck" (see "DDR on DTC: Relpax").
Here's the ad that DDR reviewed:
This is probably the result of Pfizer's conservative view of what modern women aspire to at 11:00 Am in the morning (note the clock).
I couldn't find this ad in a recent issue of People Magazine, which is the publication in which DDR found the above ad. Instead I found this much more politically correct, although still not too inspirational, ad:
In this version, two hours after taking Replax, the migraine sufferer is able to go out and do whatever her business is -- probably commuting to work given that the clock is showing 8;00 AM (or is it PM?).
Perhaps Pfizer read DDR's column and revised the print ad campaign, at least as far as image is concerned. Surprisingly, however, the Replax.com Web site still portrays the woman mopping the floor:
It appears that it takes longer to swap out a Web image that a print ad image.
Pfizer is asking Replax.com visitors to tell their "stories" by submitting photos or video. "Tell us about your experience with migraines by submitting a story," says the promo page (here). "Your story can include a photo or video. If chosen, your submission could be featured on RELPAX.com."
I don't imagine a single submitted photo or video will feature a woman mopping the floor. Do you?
You can tell that pharma marketers are getting desperate when they have to beg consumers to submit stories to compensate for the fact that their image of the modern consumer dates back to the 1950's.
Thursday, August 23, 2012
Wednesday, August 22, 2012
When’s the best time to return to University?
Is there really a best time to return to university? After a few years into your career you might begin feeling less sense of achievement. Perhaps the challenges you originally thrived on are gone. The determined amongst us are contemplating our next move. That could involve a change of careers, or perhaps even climbing a rung or two higher on the career ladder.
Many people who feel this way
Many people who feel this way
Lipitor U.S. Sales Tank 70% in 2012 vs 2011!
According to Drugs.com, Lipitor U.S. sales in Q2 of 2012 were only 30% of what they were in Q2 2011 ($579 million vs. $1,949 million, respectively (see chart below; Source: http://www.drugs.com/stats/lipitor).
Meanwhile, sales of Crestor (a competitor anti-cholesterol drug) increased only somewhat during the same period (see chart below; Source: http://www.drugs.com/stats/crestor).
I conclude that most of the loss of Lipitor sales was due to direct competition from generic versions of Lipitor now currently available, which is further proof that Pfizer's "innovative" attempts to stem the generic Lipitor tide has failed (see also "Pfizer Throws In the Lipitor Marketing Towel").
Meanwhile, sales of Crestor (a competitor anti-cholesterol drug) increased only somewhat during the same period (see chart below; Source: http://www.drugs.com/stats/crestor).
I conclude that most of the loss of Lipitor sales was due to direct competition from generic versions of Lipitor now currently available, which is further proof that Pfizer's "innovative" attempts to stem the generic Lipitor tide has failed (see also "Pfizer Throws In the Lipitor Marketing Towel").
BI to Launch Beta Version of its Syrum FaceBook Game on September 13, 2012
John Pugh, Director of Digital for Boehringer Ingelheim GmbH (BI), announced that BI will release a BETA version of the FaceBook game SYRUM at a PSFK conference in London on September 13, 2012.
I have been anxiously awaiting the launch of this game after I first heard about it 10 months ago at a pharma industry conference (see "Pharma & Fun, Not Oxymoronic? Here Comes Gamification!" and "BI's Facebook Game Syrum to be Launched 'When It's Ready'"). At least BI is speedier than the FDA in delivering on long-awaited promises!
I have not heard of the PSFK conferences until now. According to its website, PSFK "conferences offer a diverse program of speakers with backgrounds in art, technology, design, marketing, and media, creating an environment where disparate ideas can come together in new ways to fuel work that changes the world for the better. We set an agenda that allows participants to meet and discuss with one another, together sharing and building upon the ideas brought forth from the stage."
I am a bit surprised, however, that Pugh/BI did not choose to launch SYRUM at a pharma industry conference such as DigiPharm Europe, which will take place less than a fortnight later, also in London. Over the past year, Pugh has been making the rounds at such industry conferences promoting SYRUM. I'm not one to speculate (ha ha), but is Pugh getting ready to move on to greener pastures in another, more "innovative" industry? To be fair, it's important for pharma company employees to make connections with like-minded people in other industries to get new ideas that may be applied to pharma.
In any case, here's some of what Pugh revealed to PSFK (read the full interview here):
Meanwhile, here's a first glimpse of actual SYRUM game screens - previously, we've only been able to see the opening screen with the message "coming soon."
I have been anxiously awaiting the launch of this game after I first heard about it 10 months ago at a pharma industry conference (see "Pharma & Fun, Not Oxymoronic? Here Comes Gamification!" and "BI's Facebook Game Syrum to be Launched 'When It's Ready'"). At least BI is speedier than the FDA in delivering on long-awaited promises!
I have not heard of the PSFK conferences until now. According to its website, PSFK "conferences offer a diverse program of speakers with backgrounds in art, technology, design, marketing, and media, creating an environment where disparate ideas can come together in new ways to fuel work that changes the world for the better. We set an agenda that allows participants to meet and discuss with one another, together sharing and building upon the ideas brought forth from the stage."
I am a bit surprised, however, that Pugh/BI did not choose to launch SYRUM at a pharma industry conference such as DigiPharm Europe, which will take place less than a fortnight later, also in London. Over the past year, Pugh has been making the rounds at such industry conferences promoting SYRUM. I'm not one to speculate (ha ha), but is Pugh getting ready to move on to greener pastures in another, more "innovative" industry? To be fair, it's important for pharma company employees to make connections with like-minded people in other industries to get new ideas that may be applied to pharma.
In any case, here's some of what Pugh revealed to PSFK (read the full interview here):
“We are taking a Silicon Valley approach,” said Pugh, “where we know we have got a really good game that’s stable but we’ll launch a beta version. We really want to make it so that we get lots of feedback from the people who are playing.”"Crowdsourcing" seems to be all the rage now in the pharmaceutical industry. See, for example, "Crowd Sourced Creative Commons Drug Information" (free subscription required).
“We’re offering rewards and prizes for people to give feedback so that we can really create the duration of the game, and develop it, and have more of a crowdsourced collaborative effort to develop the future stages of it, so the game will grow and evolve, as more people play it. This is a very unique offering from a highly regulated industry.”
Meanwhile, here's a first glimpse of actual SYRUM game screens - previously, we've only been able to see the opening screen with the message "coming soon."
Tuesday, August 21, 2012
Is the macro-environment really a PEST?
When marketing students learn to consider the macro-environment in the development of their marketing plans and strategies, they are provided with the acronym PEST as a simple way of recalling political, economic, social and technology factors.
But this view stems from the traditional business outlook that environmental change was essentially a nuisance and that stability was preferable.
But
But this view stems from the traditional business outlook that environmental change was essentially a nuisance and that stability was preferable.
But
Monday, August 20, 2012
Certifying Prescription Grade Smartphone Medical Apps
An article in yesterday's NYT focused on what I call "Prescription Grade Smartphone Medical Apps." The article said the idea of such apps "excites some people in the health care industry, who see them as a starting point for even more sophisticated applications that might otherwise never be built" (read the article here).
"But unlike a 99-cent game, apps dealing directly with medical care cannot be introduced to the public with bugs that will be fixed later. The industry is still grappling with how to ensure quality and safety." I have written about this issue before, although for apps created by the pharma industry and not "Prescription Grade" apps. See, for example:
Happtique, in July 2012, released a draft of standards that it will be using to certify medical, health, and fitness apps under Happtique’s App Certification Program. The purpose of the program is to help users identify apps that meet high operability, privacy, and security standards and are based on reliable content. You can find the Happtique certification draft standards attached to this post.
The Happtique Certification Standards include these categories:
Content Standard C1 states: "The app is based on one or more credible information sources such as an accepted protocol, published guidelines, evidence-based practice, peer-reviewed journal, etc.
Performance Requirements for Standard C1
But more troubling than the lack of documentation regarding content, is the accuracy of the apps software. Happtique Certification Security Standards address some of my concerns.
Security Standard S6 states: "The app owner has a mechanism to notify end users about apps that are banned or recalled by the app owner or any regulatory entity (e.g., FDA, FTC, FCC)."
Performance Requirements for Standard S6
"But unlike a 99-cent game, apps dealing directly with medical care cannot be introduced to the public with bugs that will be fixed later. The industry is still grappling with how to ensure quality and safety." I have written about this issue before, although for apps created by the pharma industry and not "Prescription Grade" apps. See, for example:
- Some Unregulated Physician Smartphone Apps May Be Buggy
- FDA Mobile Regulatory Fear Mongering by PhRMA
- Be Aware of What's Behind a Pharma Mobile App: Disclaimers Only Tell Part of the Story
Happtique, in July 2012, released a draft of standards that it will be using to certify medical, health, and fitness apps under Happtique’s App Certification Program. The purpose of the program is to help users identify apps that meet high operability, privacy, and security standards and are based on reliable content. You can find the Happtique certification draft standards attached to this post.
The Happtique Certification Standards include these categories:
- App Operability Standards
- App Privacy Standards
- App Security Standards
- App Content Standards
Content Standard C1 states: "The app is based on one or more credible information sources such as an accepted protocol, published guidelines, evidence-based practice, peer-reviewed journal, etc.
Performance Requirements for Standard C1
- C1.01 If the app is based on content from a recognized source (e.g., guidelines from a public or private entity), documentation (e.g., link to journal article, medical textbook citation) about the information source is provided.
- C1.02 If the app is based on content other than from a recognized source, documentation about how the content was formulated is provided, including information regarding its relevancy and reliability
But more troubling than the lack of documentation regarding content, is the accuracy of the apps software. Happtique Certification Security Standards address some of my concerns.
Security Standard S6 states: "The app owner has a mechanism to notify end users about apps that are banned or recalled by the app owner or any regulatory entity (e.g., FDA, FTC, FCC)."
Performance Requirements for Standard S6
- S6.01 In the event that an app is banned or recalled, a mechanism or process is in place to notify all users about the ban or recall and render the app inoperable.
- S6.02 In the event that the app constitutes a medical device (e.g., 510(k)) or is regulated by the FDA in any other capacity, the app owner has a policy and a mechanism in place to comply with any and all applicable rules and regulations for purposes of handling all aspects of a product notification or recall, including all corrections and removals.
Saturday, August 18, 2012
Public's Confidence in Science Remains Steady Over 38 Years, But Not So for Medicine
Michael Ritchie, Postdoctoral Fellow at Pfizer, recently posted to the Think Science Blog that he was NOT surprised that the American public "lost significant trust in the institutions of education, the executive branch of the federal government, organized religion, congress, banks/financial institutions and the press" over the period from 1973 through 2010. He cited results of a study conducted by the University of Chicago, National Opinion Research Center.
"In contrast," Richie said, "the American public’s trust in the scientific community remained virtually unchanged over this period" (see "Perspectives from a Postdoc: The Public’s Trust of Science").
Ritchie may have been using "Science community" as a surrogate for the pharmaceutical industry, which wasn't a specific category included in the study. What Ritchie didn't mention, however, is that public confidence (which is what the study actually measured, not "trust") decreased more or less "significantly" with regard to "Medicine" and "Major companies," two other -- perhaps more relevant -- surrogates for the pharmaceutical industry.
I plotted the data for Medicine, Science, Organized Religion, Major Companies, and the Press in the following chart. You can find the complete set of data here.
What do you think is the better indicator in this study for the trend in public confidence in the pharmaceutical industry? Science? Medicine? or "Major Companies?"
BTW, if you look at the public's confidence in Congress and the Executive branch of government, you will see that it bounces up and down according to the political atmosphere and whether or not we are war. It's hard to say if there was a significant decrease over the years.
"In contrast," Richie said, "the American public’s trust in the scientific community remained virtually unchanged over this period" (see "Perspectives from a Postdoc: The Public’s Trust of Science").
Ritchie may have been using "Science community" as a surrogate for the pharmaceutical industry, which wasn't a specific category included in the study. What Ritchie didn't mention, however, is that public confidence (which is what the study actually measured, not "trust") decreased more or less "significantly" with regard to "Medicine" and "Major companies," two other -- perhaps more relevant -- surrogates for the pharmaceutical industry.
I plotted the data for Medicine, Science, Organized Religion, Major Companies, and the Press in the following chart. You can find the complete set of data here.
What do you think is the better indicator in this study for the trend in public confidence in the pharmaceutical industry? Science? Medicine? or "Major Companies?"
BTW, if you look at the public's confidence in Congress and the Executive branch of government, you will see that it bounces up and down according to the political atmosphere and whether or not we are war. It's hard to say if there was a significant decrease over the years.
Subscribe to:
Posts (Atom)








